• Statement to Valirx shareholders

    June 24, 2018 | Posted by

    Following a constructive meeting with Dr Satu Vainikka and other company members last Friday at Valirx in which the 2 primary elements of our open letter were re-iterated: namely management alignment with regards to their Valirx stock holdings and the corporate capital financing approach pursued by the company in recent years, I believe that going forward […]


    June 10, 2018 | Posted by

    OPEN LETTER Dear Ms Vainikka I write this letter to you in an open format as Align Research is all about transparency and, collectively with other shareholders, as ultimate owners of the company, we believe that all shareholders should be given the courtesy of weighing up the points we raise here. Whilst not wishing to […]

  • ValiRx – Further upside in shares ahead of potential partnership news

    December 14, 2017 | Posted by

    By Richard Gill, CFA Listing on AIM in October 2006 via the reverse takeover of Azure Holdings, ValiRx (VAL) is a biotechnology oncology focused company which specialises in developing novel treatments for cancer and associated biomarkers which enable the early detection of cancer and its therapeutic intervention. The company is focussing on the development of […]